Skip to main content

Table 2 Eligibility for Short Course Regimen by Clinical Criteria and DST Performed. a. Participants with MDR-TB Eligible for Short Course Treatment, by DST Performed

From: Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Resistance Status Xpert Only, N = 559 2nd-Line LPA Only,a N = 466 Testing R, FQ, INJ, Z, and E, N = 432b Testing R, FQ, INJ, Z, E, Eto, and Cfz, N = 407b
  # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c
Eligible for Short Course 559 / 559 (100) 118 / 466 (25.3) 16 / 432 (3.7) 14 / 407 (3.4)
Resistant to FQ or INJ N/A 348 / 466 (74.7) 320 / 432 (74.1) 304 / 407 (74.7)
Resistant to Z or E N/A N/A 408 / 432 (94.4) 386 / 407 (94.8)
Resistant to FQ, INJ, Z, or E N/A N/A 416 / 432 (96.3) 391 / 407 (96.1)
Resistant to FQ, INJ, Z, E, Eto, or Cfz N/A N/A N/A 393 / 407 (96.6)
  1. a2nd-line LPA tests for susceptibility to isoniazid, rifampin, fluoroquinolones, and 2nd-line injectables (amikacin, capreomycin, or kanamycin)
  2. bR rifampin, FQ fluoroquinolone, INJ 2nd-line injectable, Z pyrazinamide, E ethambutol, Eto ethionamide, Cfz clofazimine
  3. cPercentages reported reflect number of participants with resistance or susceptibility divided by number of participants who completed susceptibility testing for each drug. As a result, the number of participants in the denominator is not the same in all rows